89bio (ETNB) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about 89bio in November 2026.
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
89bio (ETNB) Stock Forecast
Analyst price target, next 12 months
$29.83
+101.0% vs today's $14.84
Price range over the last 12 months
Close to its 12-month high
Analysts covering 89bio have a consensus 12-month target of $29.83, above the current price of $14.84.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 16 Apr 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying 89bio Inc’s stock, indicating strong potential for future growth.
Financial Health
89bio Inc is showing promising financial strength with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.